|
|
Research progress on the mechanism of traditional Chinese medicine compounds in the treatment of non-alcoholic fatty liver disease base on autophagy |
TAN Liping1 SHI Anhua2 ZHU Xiaosong1 DENG Xue3 LI Jixiao3 CHEN Wenhui4 |
1.School of Basic Medicine, Yunnan University of Chinese Medicine, Yunnan Province, Kunming 650500, China;
2.the Personnel Department, Yunnan University of Chinese Medicine, Yunnan Province, Kunming 650500, China;
3.College of Traditional Chinese Medicine, Yunnan University of Chinese Medicine, Yunnan Province, Kunming 650500, China;
4.Department of Science and Technology, Yunnan University of Chinese Medicine, Yunnan Province, Kunming 650500, China |
|
|
Abstract Autophagy of liver is closely related to the occurrence and development of non-alcoholic fatty liver disease (NAFLD). The autophagy level of hepatocytes decreased in the stage of nonalcoholic simple fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH). In the stage of hepatic fibrosis (HF), autophagy of HSCS increases, this leads to the development of the disease. Therefore, a clear understanding of the change rules and specific signal pathways of liver autophagy in different stages of NAFLD is conducive to the regulation and control of the level of liver autophagy and the alleviation of lesions. In this paper, we find that different traditional Chinese medicine compounds with different syndrome differentiation and treatment can enhance or inhibit liver′s autophagy in different stages of NAFLD, which provides new ideas for basic and clinical research of NAFLD.
|
|
|
|
|
[1] 胡中杰,张晶.我国非酒精性脂肪性肝病的研究现状[J].临床肝胆病杂志,2016,32(30):552-556.
[2] 李婕.亚洲地区非酒精性脂肪性肝病的流行病学特点[J].临床肝胆病杂志,2018,34(12):2515-2519.
[3] Estes C,Anstee QM,Teresa Arias-Loste M,et al. Modeling NAFLD disease Burden in China,France,Germany,Italy,Japan,Spain,United Kingdom,and United States for the period 2016-2030 [J]. J Hepatol,2018,69(4):896-904.
[4] Ashford TP,Porter KR. Cytoplasmic components in hepatic cell lysosomes [J]. J Cell Biol,1962,12(1):198-202.
[5] Shintani T,Klionky DJ. Autophagy in health and disease:a double-edged sword [J]. Science,2004,306(5698):990-995.
[6] 王鑫焱,刘文兰.自噬参与肝纤维化的机制[J].世界华人消化杂志,2018,26(23):1415-1422.
[7] Yang L,Li P,Fu S,et al. Defective hepatic autophagy in obesity promotes ER stress and causes insulin resistance [J]. Cell Metab,2010,11(6):467-478.
[8] Koga H,Kaushik S,Cuervo AM. Altered lipid content inhibits autophagic vesicular fusion [J]. FASEB J,2010,24(8):3052-3065.
[9] 郭亮,汤其群.非酒精性脂肪肝发病机制和治疗的研究进展[J].生命科学,2018,30(11):1165-1172.
[10] 周帆,彭君伟,范伏岗,等.自噬与氧化应激在非酒精性脂肪性肝病发病机制中的关系[J].临床肝胆病杂志,2018, 34(8):1805-1808.
[11] Hernández-Gea V,Ghiassi-Nejad Z,Rozenfeld R,et al. Autophagy releases lipid that promotes fibrogenesis by activa ted hepatic stellate cells in mice and in human tissues [J]. Gastroenterology,2012,142(4):938-946.
[12] Lodder J,Dena?觕s T,Chobert MN,et al. Macrophage autophagy protects against liver fibrosis in mice [J]. Autophagy,2015,11(8):1280-1292.
[13] 董晞,张浩军,赵世萍,等.糖肾方对自发性2型糖尿病模型大鼠脂代谢及肝脏脂变的影响[J].中华中医药杂志,2010,25(11):1778-1781.
[14] 朱超,黄敏,梁琼麟,等.糖肾方对自发性Ⅱ型糖尿病鼠磷脂代谢的影响[J].高等学校化学学报,2011,32(7):1512-1518.
[15] Wang Y,Zhao H,Li X,et al. Tangshen Formula Alleviates Hepatic Steatosis by Inducing Autophagy Through the AMPK/SIRT1 Pathway [J]. Front Physiol,2019,10:44.
[16] 张渐轩,陈雁,李柳梅,等.脂肝方对NASH肝细胞自噬、线粒体及其能量代谢的影响[J].广西中医药大学学报,2017,20(2):1-4.
[17] 李蓓蕾,张勇,谢博文,等.脂肝方对非酒精性脂肪性肝炎肝细胞线粒体选择性自噬机制的干预效应[J].中华中医药杂志,2019,34(1):109-113.
[18] 毛堂友,高康丽,赵唯含,等.温运清利法对非酒精性脂肪性肝炎大鼠肝组织DAG-PKCε信号通路的作用研究[J].环球中医药,2016,9(8):908-913.
[19] 郭一,李军祥,毛堂友,等.自噬相关蛋白在高脂饲料诱导的非酒精性脂肪性肝炎大鼠肝脏中的表达及茵陈苓桂术甘汤的干预效应[J].中华中医药学刊,2018,36(4):798-801.
[20] 李长新,周滔,牛柯敏,等.调肝理脾法对大鼠非酒精性脂肪性肝病脂质代谢和自噬相关蛋白-1表达的影响[J].中西医结合肝病杂志,2018,28(5):290-293.
[21] 李长新,周滔,牛柯敏,等.调肝理脾法对非酒精性脂肪性肝病大鼠模型脂质代谢及微管相关蛋白轻链3B表达的影响[J].临床肝胆病杂志,2018,34(4):829-835.
[22] 安祯祥,何远利,王敏.芒硝外敷联合扶脾柔肝颗粒内服治疗肝硬化腹水的临床研究[J].辽宁中医杂志,2016,43(9):1900-1902.
[23] 安祯祥,何远利,王敏,等.扶脾柔肝方对肝纤维化大鼠自噬相关蛋白Beclin-1及LC3-Ⅱ表达的影响[J].中药新药与临床药理,2019,30(6):639-646.
[24] 安祯祥,何远利,王敏,等.扶脾柔肝方含药血清对大鼠原代肝星状细胞上皮间质转化及自噬的影响[J].中药新药与临床药理,2019,30(4):408-415.
[25] 姜辉,张家富,高家荣,等.疏肝健脾方对肝纤维化大鼠自噬蛋白Beclin-1和LC3-Ⅱ的影响[J].中国中西医结合杂志,2017,37(8):955-960.
[26] 王宝玉.益气活血方调节肝脏细胞自噬及逆转肝纤维化机制的研究[D].石家庄:河北医科大学,2017.
[27] 韩雪,张睦清,张一昕,等.泽泻汤加味方对高脂血症大鼠肝细胞水甘油通道蛋白9表达的影响[J].中药药理与临床,2018,34(5):7-10.
[28] Xu L,Jing M,Yang L,et al. The Alisma and Rhizoma decoction abates nonalcoholic steatohepatitis-associated liver injuries in mice by modulating oxidative stress and?autophagy [J]. BMC Complement Altern Med,2019,19(1):92.
[29] 李志国,姜韩雪,焦云涛,等.非酒精性脂肪性肝病中医证型分布的文献分析[J].中华中医药杂志,2017,32(10):4713-4715.
[30] 张夏,罗伟生,胡振斌,等.非酒精性脂肪肝中医药研究进展[J].辽宁中医药大学学报,2018,20(7):180-182. |
|
|
|